Sanjay Agarwal, an alumnus of Harvard Business School and an executive from Wharton Business School, is also a rank holder Chartered Accountant and Cost Accountant with over 25 years of experience in corporate finance, investment banking and consumer goods industry. In his last corporate role as the Chief Financial Officer of Jyothy Labs Limited, a leading FMCG company, his varied experience and deep financial expertise led to immense value creation for the organization. PI Industries operates in the domestic agricultural inputs and custom synthesis manufacturing (CSM) exports segments. It is a leading player in the domestic agricultural inputs sector, primarily dealing in agrochemicals and plant nutrients. The pesticides maker registered 17.21% increase in consolidated net profit to Rs 448.8 crore on 8.3% rise in revenue to Rs 2,068.9 crore in Q1 FY25 as compared with Q1 FY24. The scrip declined 0.42% to currently trade at Rs 4,403.85 on Monday, 26 August 2024.Powered by Capital Market - Live

P I Industries announced that the acquisition of Plant Health Care Plc, a UK incorporated company traded on AIM, a market operated by the London Stock Exchange by PI Industries Management Consultancies L.L.C., a wholly owned subsidiary of the Company (PI LLC) by means of a court-sanctioned scheme of arrangement has been completed. With effectiveness of the Scheme, Plant Health Care Plc has become wholly owned subsidiary of PI LLC and a step down subsidiary of the Company, on and from 20 August 2024. Powered by Capital Market - Live

Domestic revenues were subdued mainly due to delayed sowing and erratic spread of monsoon although favourable product mix and improved working capital management helped in containing the financial impact. Biologicals products improved growth and revenue increase by about 39% YoY. 14% growth in Agchem exports were mainly driven by volumes and growth of new products, which was 24% YoY. Pharma contributed exports revenue of Rs 25.3 crore, dipped due to supply deferment of a few products. The firm's overheads increase attributable to the scale-up of exports and promotion expenses for the launch of the new products (11%) and newly acquired Pharma businesses (5%). EBITDA improved by 24% to Rs 585.3 crore in Q1 FY25 from Rs 472.6 crore in same quarter last year. Gross margin and EBITA margin for June 2024 quarter were at 52% (up 526 bps YoY) and 28% (up 356 bps YoY), respectively. The company's Gross Margin and EBITDA improved mainly on account of favorable product mix and operating leverage. PI Industries operates in the domestic agricultural inputs and custom synthesis manufacturing (CSM) exports segments. It is a leading player in the domestic agricultural inputs sector, primarily dealing in agrochemicals and plant nutrients. Powered by Capital Market - Live

Net profit of P I Industries rose 17.21% to Rs 448.80 crore in the quarter ended June 2024 as against Rs 382.90 crore during the previous quarter ended June 2023. Sales rose 8.30% to Rs 2068.90 crore in the quarter ended June 2024 as against Rs 1910.40 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales2068.901910.40 8 OPM %28.1924.49 - PBDT649.70515.10 26 PBT566.30445.40 27 NP448.80382.90 17 Powered by Capital Market - Live